Richard J Benjamin
Overview
Explore the profile of Richard J Benjamin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norris P, Stone M, Di Germanio C, Balasko B, Kaidarova Z, Friend H, et al.
Transfusion
. 2025 Jan;
PMID: 39801369
Background: Although alloimmunization risk of pathogen-reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs). Study Design And Methods: In a Phase...
2.
Karim C, Panigrahi A, Pearl R, Sodha N, Beaver T, Pelletier J, et al.
Transfusion
. 2024 Dec;
65(2):344-353.
PMID: 39719927
Background: The clinical significance of natural and treatment-emergent antibodies specific for amustaline/glutathione pathogen-reduced red blood cells (PRRBCs) is not known. Study Design And Methods: A Phase 3, randomized clinical trial...
3.
North A, Ling K, Ricaud G, Stankowski Jr L, Daly J, Bentow S, et al.
Transfusion
. 2024 May;
64(6):1097-1108.
PMID: 38716879
Background: N-(-9 acridinyl)-b-alanine hydrochloride (S-300) is the main byproduct of red blood cell (RBC) amustaline/glutathione(GSH) pathogen reduction, currently undergoing phase III US clinical trials following successful European studies(1-3). Phosphatidylinositol glycan,...
4.
Wheeler A, Snyder E, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Blood Adv
. 2024 Mar;
8(9):2290-2299.
PMID: 38447116
Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do...
5.
Snyder E, Sekela M, Welsby I, Toyoda Y, Alsammak M, Sodha N, et al.
Trials
. 2023 Dec;
24(1):799.
PMID: 38082326
Background: Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from...
6.
7.
Pitman J, Payrat J, Park M, Liu K, Corash L, Benjamin R
Transfusion
. 2023 Feb;
63(4):711-723.
PMID: 36802055
Background: France converted to universal pathogen reduced (PR; amotosalen/UVA) platelets in 2017 and extended platelet component (PC) shelf-life from 5- to 7-days in 2018 and 2019. Annual national hemovigilance (HV)...
8.
Gammon R, Katz L, Strauss D, Rowe K, Menitove J, Benjamin R, et al.
Transfus Med
. 2022 Aug;
33(1):6-15.
PMID: 35918741
The COVID-19 pandemic severely tested the resilience of the US blood supply with wild fluctuations in blood donation and utilisation rates as community donation opportunities ebbed and hospitals post-poned elective...
9.
Cancelas J, Genthe J, Stolla M, Rugg N, Bailey S, Nestheide S, et al.
Transfusion
. 2022 Jul;
62(8):1619-1629.
PMID: 35808974
Background: Amotosalen/UVA pathogen-reduced platelet components (PRPCs) with storage up to 7 days are standard of care in France, Switzerland, and Austria. PRPCs provide effective hemostasis with reduced risk of transfusion-transmitted...
10.
Snyder E, Wheeler A, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Transfusion
. 2022 Jun;
62(7):1365-1376.
PMID: 35748490
Background: Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and...